^
    Back
    Association details:
    Biomarker:PAX5-JAK2 fusion
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2023
    Title:

    Synergy of Ruxolitinib and Carfilzomib in Targeting the PAX5::JAK2 fusion I n Vitro: Potential Therapeutic Advantage for a Subset of Ph-like Acute Lymphoblastic Leukemia

    Published date:
    11/02/2023
    Excerpt:
    RUX, CFZ and BTZ were all effective against PAX5::JAK2 transfected Ba/F3 cells with a median lethal dose (LD50) of 514nM...We showed in vitro that RUX, CFZ and BTZ are all potent against the high risk PAX5::JAK2 fusion. RUX and CFZ in combination demonstrated moderate synergy against PAX5::JAK2 and inhibited proliferation...
    Secondary therapy:
    carfilzomib
    DOI:
    https://doi.org/10.1182/blood-2023-174423
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    N Engl J Med
    Title:

    Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

    Excerpt:
    Cells expressing ABL2, CSF1R, and JAK2 fusions have enhanced STAT5 activation, which is inhibited by dasatinib in RCSD1–ABL2 and SSBP2–CSF1R and by ruxolitinib in PAX5–JAK2.
    DOI:
    https://dx.doi.org/10.1056%2FNEJMoa1403088